AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04017715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: cool down
Description: Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition
Study NCT04017715 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention: control
Description: sprint exercise and general stretching as conventional protocol as follows in star club
Study NCT04959409 — intervention group
Intervention type: DRUG
Intervention: Topical analgesia (EMLA or AMETOP)
Description: Whether topical analgesia has or has not been administered to each child prior to them receiving an inhalational induction of anaesthesia
Study NCT03191565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper diary sheet
Description: Writing skill-use and symptoms on a week matrix type sheet
Study NCT03191565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monsenso DBT-app and IT monitoring program
Description: Entering skill-use and symptoms on a smartphone with Monsenso DBT-app and IT monitoring program
Study NCT01559610 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Intervention Group
Description: The patients were instructed by a nurse
Study NCT01559610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention Group
Description: The patients were instructed by a nurse
Study NCT00734708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin (genetical recombination)
Description: Administered to the bone defect during flap operation
Study NCT00734708 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control
Study NCT03963219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABC4D
Description: The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
Study NCT03963219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bolus Calculator
Description: Standard bolus calculator
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rest (Sitting on chair)
Description: Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rest (Sitting on chair)
Description: Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rest (Sitting on chair)
Description: Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cycling exercise
Description: Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling exercise
Description: Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cycling exercise
Description: Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 50% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
Study NCT02252302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol inhalation
Description: Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Study NCT02252302 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Salbutamol inhalation
Description: Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
Study NCT02252302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation
Description: Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diesel Exhaust Exposure
Description: Participants will be exposed to PM2.5 of 300 μg/m3
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diesel Exhaust Exposure
Description: Participants will be exposed to PM2.5 of 300 μg/m3
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Filtered air
Description: Participants will be breathing filtered air
Study NCT02252302 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Filtered air
Description: Participants will be breathing filtered air
Study NCT00329693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norprolac
Description: Placebo
Study NCT00329693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norprolac
Description: Quinagolide
Study NCT02437994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
Study NCT01984957 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Muscle biopsy
Description: open muscular biopsy of the deltoid under local anaesthesia
Study NCT00410072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
Study NCT00410072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Tenofovir
Description: Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
Study NCT03576443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Idelalisib 150 mg x 2 p o
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: Pharmaceutical form: Liquid solution Route of administration : Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Description: Pharmaceutical form: Lyophilized powder combined with liquid component Route of administration : Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form: Lyophilized live virus vaccine Route of administration : Subcutaneous
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine
Description: Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine
Description: Pharmaceutical form: Powder and suspension for injection Route of administration: Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Pentavalent
Description: Pharmaceutical form: Oral solution Route of administration: Oral
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus Vaccine, Live, Pentavalent
Description: Pharmaceutical form: Oral solution Route of administration: Oral
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT03630705 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
Study NCT01470703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECMO (Quadrox®, Jostra®, Maquet®)
Description: ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure \<25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level \<25 cm H2O and low pressure level ≥10 cm H2O
Study NCT01470703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional care
Description: Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 \<80% for >6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
Study NCT04090385 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
Study NCT04090385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Participants will receive 15 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, 5 times a week. The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
Study NCT03493438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.
Study NCT03493438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.
Study NCT02627573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unrelated allogeneic stem cell transplantation
Study NCT02627573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Study NCT02627573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Study NCT02627573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Study NCT02627573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT02627573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02627573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Study NCT01290952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off-pump bypass surgery
Description: is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
Study NCT01290952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On-pump bypass surgery
Description: is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
Study NCT01680809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression stocking 15-20mmHg
Description: Compression stocking with 15-20mmHg of compression
Study NCT01680809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression stocking 20-30mmHg
Description: Compression stocking with 20-30mmHg of compression
Study NCT02576977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg IV infusion
Study NCT02576977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: pomalidomide 4 mg capsules
Study NCT02576977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: pomalidomide 4 mg capsules
Study NCT02576977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone 40 mg tablets
Study NCT02576977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone 40 mg tablets
Study NCT00762034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Induction therapy 500 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
Study NCT00762034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
Study NCT00762034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Induction therapy 200 mg/m\^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
Study NCT00762034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
Study NCT00762034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
Study NCT00762034 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
Study NCT00762034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
Study NCT00762034 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
Study NCT00762034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
Study NCT01956188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA and DHA supplementation
Description: Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
Study NCT01956188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given 3g/d of soy oil - 5 capsules per day.
Study NCT05643989 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stoma formation
Description: Trocar placement: the optical trocar (10 mm) will be inserted just near umbilicus . An abdominal revision is performed to determine the location of the tumor. Colon in 10 sm proximally to tumor is prepared for the discharge stoma formation. In the corresponding location on the anterior abdominal wall is formed incision of skin and subcutaneous tissue to the aponeurosis, the cut length is 2.5 sm. After that, aponeurosis crucial incision is performed. The previously prepared colon is brought out to the anterior abdominal wall with the help of a grasper. Discharge stoma is attached to a holding device; colon is fixed by the interrupted sutures (Polysorb 3-0). In the operating room, the stoma is opened, the intestinal patency is checked in both directions, and hemostasis is revealed. With the help of optics, the presence of intestinal tension is checked; if necessary, the colon is additionally mobilized.